Gilead­'s M&A streak car­ries on with buy­out of pri­vate PARP1, au­toim­mune biotech

Gilead’s deal­mak­ing spree, part of bio­phar­ma’s “blis­ter­ing” M&A this year, con­tin­ued on Tues­day with a con­sum­ma­tion of on­col­o­gy and in­flam­ma­tion start­up XinThera.

Af­ter deals for UK start­up Miro­Bio, a Jounce an­ti­body and Tmu­ni­ty — while pass­ing on Pi­o­nyr — Gilead is now fur­ther ex­pand­ing be­yond its HIV prod­ucts with a biotech near­ing the clin­ic with two oral small mol­e­cule PARP1 in­hibitors for var­i­ous tu­mors. Part of the DNA-re­pair­ing en­zyme fam­i­ly, PARP is tar­get­ed by the likes of As­traZeneca’s Lyn­parza and GSK and Tesaro’s Ze­ju­la, but dose-lim­it­ing tox­i­c­i­ties lim­it their use. Mer­ck KGaA, Duke Street Bio and oth­ers are in­ter­est­ed in next-gen moves.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER